U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

i
i
Up-to-Date Info : To find the latest CDC information on this topic go to:

Grading of recommendations, assessment, development, and evaluation (GRADE) : Pfizer-BioNTech COVID-19 vaccine for persons aged 12-15 years

Supporting Files Public Domain
File Language:
English


Details

  • Corporate Authors:
    National Center for Immunization and Respiratory Diseases (U.S.)
  • Description:
    A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine for persons aged 12-15 years was presented to the Advisory Committee for Immunization Practices (ACIP) on May 12, 2021. GRADE evidence type indicates the certainty in estimates from the available body of evidence. Evidence certainty ranges from type 1 (high certainty) to type 4 (very low certainty) [1].

    The policy question was, “Should vaccination with Pfizer-BioNTech COVID-19 vaccine be recommended for persons 12-15 years of age during an Emergency Use Authorization?” The potential benefits pre-specified by the ACIP COVID-19 Vaccines Work Group included prevention of symptomatic laboratory-confirmed COVID-19 (critical), hospitalization due to COVID-19 (important), multisystem inflammatory syndrome in children (MIS-C) (important), SARS-CoV-2 seroconversion (important), and asymptomatic SARS-CoV-2 infection (important). The two pre-specified harms were serious adverse events (critical) and reactogenicity grade ≥3 (important).

    A systematic review of evidence on the efficacy and safety of a two-dose regimen of Pfizer-BioNTech COVID-19 vaccine among persons aged 12-15 years was conducted. The quality of evidence from one Phase II/III randomized controlled trial was assessed using a modified GRADE approach.

  • Content Notes:
    Overview -- Introduction -- Methods -- Results -- GRADE Summary.
  • Subjects:
  • Document Type:
    Webpage
  • Name as Subject:
  • Place as Subject:
    United States
  • Collection(s):
  • Main Document Checksum:
    urn:sha256:3ffec3e8634aeab53d42a7c94176878dc17a4707f47bd533ba63d6ef7f2c1514
  • Download URL:
  • File Type:
    Filetype[PDF - 149.00 KB ]
PREVIOUS
File Language:
English
ON THIS PAGE
Details Supporting Files
CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
BACK TO TOP